Visi / OTC Markets / Bioxcel Therapeutics

Bioxcel Therapeutics

Bioxcel Therapeutics

Investuok be komisinių

Pirk ir parduok dalines akcijas vos už 1 €

Informacija ir statistika

Dienos intervalas
1 D.−100,00 %
3 MĖN.−100,00 %
1 SAV.−100,00 %
6 MĖN.−100,00 %
1 MĖN.−100,00 %
1 M.−100,00 %
SIMBOLIS
BTAIQ
RINKA
OTC Markets
ISIN
US09075P2048

Data

Uždara

Pokytis

Pokytis (%)

Atvira

Didelė

Maža

0,060,000 %0,060,070,05
0,070,0114,29 %0,060,080,05
0,070,0228,57 %0,050,070,04
0,050,0120 %0,040,050,04
0,050,0120 %0,040,060,04
0,050,000 %0,050,060,05
0,050,000 %0,050,060,04
0,060,0233,33 %0,040,060,03
0,040,0250 %0,020,040,02
0,07−0,02−28,57 %0,090,090,07
0,120,000 %0,120,130,11
0,11−0,02−18,18 %0,130,200,11
0,140,000 %0,140,140,12
0,160,016,25 %0,150,170,14
0,18−0,03−16,67 %0,210,230,16
0,72−0,03−4,17 %0,750,760,70
0,780,022,56 %0,760,790,74
0,74−0,04−5,41 %0,780,800,71
0,76−0,04−5,26 %0,800,830,75
0,80−0,02−2,5 %0,820,860,79
0,80−0,03−3,75 %0,830,830,80
0,830,044,82 %0,790,860,79
0,79−0,06−7,59 %0,850,900,78
0,89−0,13−14,61 %1,021,030,85
1,190,097,56 %1,101,241,02
1,130,032,65 %1,101,161,07
1,060,109,43 %0,961,080,96
0,93−0,04−4,3 %0,971,020,93
0,930,033,23 %0,900,960,89
0,900,055,56 %0,850,920,84
0,83−0,01−1,2 %0,840,850,80
0,84−0,03−3,57 %0,870,880,84
0,860,000 %0,860,890,86
0,850,044,71 %0,810,880,80
0,810,022,47 %0,790,840,78
0,790,000 %0,790,810,75
0,80−0,04−5 %0,840,850,79
0,85−0,03−3,53 %0,880,880,83
0,870,022,3 %0,850,870,84
0,85−0,04−4,71 %0,890,890,83
0,87−0,01−1,15 %0,880,900,84
0,88−0,03−3,41 %0,910,920,87
0,900,011,11 %0,890,910,86
0,88−0,01−1,14 %0,890,920,84
0,890,033,37 %0,860,890,80
0,87−0,04−4,6 %0,910,930,85
0,92−0,11−11,96 %1,041,050,89
1,030,1514,56 %0,881,170,88
0,880,077,95 %0,810,930,81
0,82−0,01−1,22 %0,830,870,79
0,840,044,76 %0,800,880,74
0,80−0,24−30 %1,041,040,79
1,04−0,07−6,73 %1,111,121,04
1,10−0,25−22,73 %1,351,351,10
1,38−0,01−0,72 %1,391,421,34
1,37−0,01−0,73 %1,381,411,36
1,41−0,01−0,71 %1,421,421,38
1,400,107,14 %1,301,451,29
1,310,064,58 %1,251,311,25
1,25−0,09−7,2 %1,341,341,24
1,310,032,29 %1,281,361,27
1,26−0,02−1,59 %1,281,321,25
1,300,107,69 %1,201,301,20
1,200,000 %1,201,231,17
1,190,000 %1,191,261,18
1,200,043,33 %1,161,201,14
1,160,000 %1,161,261,16
1,140,043,51 %1,101,161,10
1,11−0,01−0,9 %1,121,151,08
1,090,021,83 %1,071,111,06
1,07−0,03−2,8 %1,101,121,05
1,10−0,04−3,64 %1,141,141,09
1,10−0,12−10,91 %1,221,221,10
1,230,075,69 %1,161,271,15
1,16−0,04−3,45 %1,201,201,16
1,190,010,84 %1,181,241,16
1,190,000 %1,191,201,15
1,17−0,11−9,4 %1,281,281,16
1,26−0,05−3,97 %1,311,361,26
1,310,096,87 %1,221,411,22
1,220,097,38 %1,131,231,13
1,13−0,02−1,77 %1,151,171,13
1,140,054,39 %1,091,141,08
1,090,000 %1,091,101,07
1,08−0,07−6,48 %1,151,151,08
1,13−0,03−2,65 %1,161,191,12
1,14−0,03−2,63 %1,171,201,14
1,210,032,48 %1,181,221,16
1,19−0,01−0,84 %1,201,201,17
1,19−0,02−1,68 %1,211,211,17
1,200,000 %1,201,241,19
1,220,000 %1,221,261,19
1,24−0,08−6,45 %1,321,321,21
1,300,053,85 %1,251,371,24
1,25−0,01−0,8 %1,261,311,25
1,260,053,97 %1,211,281,20
1,20−0,03−2,5 %1,231,291,15
1,230,1613,01 %1,071,251,06
1,04−0,02−1,92 %1,061,071,02
1,06−0,04−3,77 %1,101,101,05
1,090,021,83 %1,071,141,07
1,06−0,04−3,77 %1,101,101,06
1,10−0,07−6,36 %1,171,171,09
1,15−0,01−0,87 %1,161,231,13
1,15−0,07−6,09 %1,221,221,15
1,200,086,67 %1,121,211,12
1,150,054,35 %1,101,251,10
1,070,000 %1,071,091,01
1,05−0,02−1,9 %1,071,141,05
1,060,054,72 %1,011,081,01
1,02−0,02−1,96 %1,041,081,01
1,06−0,03−2,83 %1,091,111,06
1,080,000 %1,081,151,07
1,10−0,05−4,55 %1,151,181,08
1,09−0,05−4,59 %1,141,141,06
1,14−0,07−6,14 %1,211,221,12
1,180,032,54 %1,151,221,08
1,22−0,16−13,11 %1,381,411,19
1,340,128,96 %1,221,351,21
1,21−0,06−4,96 %1,271,281,15
1,26−0,15−11,9 %1,411,421,25
1,37−0,04−2,92 %1,411,441,35
1,43−0,02−1,4 %1,451,491,40
1,43−0,03−2,1 %1,461,471,40
1,47−0,06−4,08 %1,531,541,46
1,51−0,09−5,96 %1,601,611,49
1,60−0,01−0,63 %1,611,621,55
1,65−0,04−2,42 %1,691,711,60
1,730,137,51 %1,601,751,59
1,540,042,6 %1,501,581,50
1,49−0,08−5,37 %1,571,611,47
1,55−0,02−1,29 %1,571,601,53
1,570,010,64 %1,561,631,54
1,55−0,13−8,39 %1,681,781,45
1,730,2715,61 %1,461,791,44
1,48−0,08−5,41 %1,561,601,47
1,61−0,21−13,04 %1,821,831,58
1,650,053,03 %1,601,671,57
1,600,000 %1,601,631,54
1,63−0,02−1,23 %1,651,671,59
1,67−0,09−5,39 %1,761,781,63
1,760,084,55 %1,681,771,63
1,660,021,2 %1,641,671,60
1,640,021,22 %1,621,731,59
1,630,063,68 %1,571,631,53
1,57−0,02−1,27 %1,591,621,55
1,620,042,47 %1,581,621,53
1,580,010,63 %1,571,611,53
1,58−0,01−0,63 %1,591,601,52
1,580,021,27 %1,561,601,54
1,54−0,08−5,19 %1,621,631,52
1,62−0,03−1,85 %1,651,651,53
1,660,106,02 %1,561,721,55
1,570,031,91 %1,541,591,47
1,500,128 %1,381,531,38
1,37−0,13−9,49 %1,501,501,36
1,49−0,08−5,37 %1,571,601,45
1,570,000 %1,571,601,48
1,58−0,02−1,27 %1,601,631,56
1,59−0,02−1,26 %1,611,621,52
1,62−0,08−4,94 %1,701,701,60
1,68−0,09−5,36 %1,771,781,67
1,770,010,56 %1,761,791,70
1,77−0,09−5,08 %1,861,861,76
1,82−0,01−0,55 %1,831,871,80
1,81−0,03−1,66 %1,841,841,76
1,84−0,05−2,72 %1,891,961,82
1,890,010,53 %1,882,081,84
1,84−0,07−3,8 %1,911,961,84
1,91−0,10−5,24 %2,012,011,91
1,99−0,06−3,02 %2,052,051,92
2,050,031,46 %2,022,081,93
2,020,020,99 %2,002,021,87
2,010,010,5 %2,002,031,92
2,00−0,04−2 %2,042,041,87
2,040,2311,27 %1,812,121,79
1,74−0,07−4,02 %1,811,821,71
1,790,073,91 %1,721,811,70
1,700,074,12 %1,631,701,59
1,600,074,38 %1,531,601,52
1,530,000 %1,531,581,50
1,56−0,07−4,49 %1,631,641,54
1,66−0,02−1,2 %1,681,701,65
1,710,000 %1,711,731,66
1,73−0,02−1,16 %1,751,751,66
1,74−0,01−0,57 %1,751,791,68
1,73−0,09−5,2 %1,821,881,71
1,830,000 %1,831,851,78
1,80−0,08−4,44 %1,881,901,80
1,880,000 %1,881,941,85
1,87−0,16−8,56 %2,032,031,87
2,01−0,13−6,47 %2,142,171,98
2,07−0,09−4,35 %2,162,192,07
2,190,052,28 %2,142,302,09
2,13−0,08−3,76 %2,212,242,08
2,200,083,64 %2,122,272,07
2,07−0,05−2,42 %2,122,162,05
2,090,178,13 %1,922,111,90
1,910,042,09 %1,871,921,82
1,87−0,22−11,76 %2,092,091,86
2,06−0,11−5,34 %2,172,192,02
2,250,135,78 %2,122,322,10
2,080,146,73 %1,942,141,93
1,91−0,02−1,05 %1,931,961,87
1,950,073,59 %1,882,081,87
1,910,168,38 %1,751,921,72
1,790,052,79 %1,741,901,74
1,74−0,10−5,75 %1,841,871,74
1,840,031,63 %1,811,851,73
1,830,1910,38 %1,641,851,63
1,630,053,07 %1,581,671,53
1,61−0,10−6,21 %1,711,731,56
1,71−0,12−7,02 %1,831,881,67
2,020,125,94 %1,902,071,87
1,930,052,59 %1,882,021,82
1,830,084,37 %1,751,881,68
1,78−0,09−5,06 %1,871,871,75
1,860,010,54 %1,851,931,83
1,86−0,02−1,08 %1,882,001,84
1,90−0,10−5,26 %2,002,001,90
2,050,010,49 %2,042,071,98
2,02−0,07−3,47 %2,092,141,98
2,07−0,11−5,31 %2,182,182,05
2,18−0,10−4,59 %2,282,282,15
2,28−0,06−2,63 %2,342,402,26
2,330,052,15 %2,282,452,24
2,260,062,65 %2,202,282,14
2,220,062,7 %2,162,302,13
2,20−0,05−2,27 %2,252,292,18
2,29−0,04−1,75 %2,332,392,28
2,31−0,15−6,49 %2,462,472,26
2,46−0,23−9,35 %2,692,702,42
2,68−0,02−0,75 %2,702,752,61
2,620,010,38 %2,612,712,52
2,610,041,53 %2,572,642,50
2,54−0,26−10,24 %2,802,802,51
2,780,051,8 %2,732,872,68
2,660,207,52 %2,462,702,46
2,50−0,07−2,8 %2,572,572,42
2,550,041,57 %2,512,612,48
2,53−0,10−3,95 %2,632,692,47
2,640,041,52 %2,602,702,52
2,570,072,72 %2,502,602,50
2,56−0,05−1,95 %2,612,612,48
2,62−0,15−5,73 %2,772,852,52
2,70−0,23−8,52 %2,932,962,66
2,820,217,45 %2,612,852,53
2,580,093,49 %2,492,582,47
2,47−0,28−11,34 %2,752,822,47
2,78−0,11−3,96 %2,892,952,78
2,99−0,01−0,33 %3,003,112,94
3,010,031 %2,983,192,95
2,90−0,08−2,76 %2,983,052,86
2,99−0,17−5,69 %3,163,162,97
3,170,175,36 %3,003,182,92
3,11−0,28−9 %3,393,413,09
3,39−0,14−4,13 %3,533,753,35
3,52−0,08−2,27 %3,603,953,51
3,58−0,35−9,78 %3,933,933,57
4,230,4711,11 %3,764,293,76
3,790,236,07 %3,564,033,56
3,570,092,52 %3,483,723,48
3,62−0,13−3,59 %3,753,753,41
3,80−0,18−4,74 %3,984,203,78
4,05−0,04−0,99 %4,094,093,80
4,100,204,88 %3,904,263,81
3,96−0,95−23,99 %4,915,193,93
5,240,275,15 %4,975,254,74
5,160,265,04 %4,905,184,71
4,98−0,28−5,62 %5,265,604,90
5,230,377,07 %4,865,424,70
5,040,101,98 %4,945,224,46
4,92−0,02−0,41 %4,945,344,78
5,67−1,18−20,81 %6,856,855,47
5,480,8315,15 %4,655,494,18
4,75−0,26−5,47 %5,016,234,61
5,60−1,69−30,18 %7,297,355,19
6,801,1817,35 %5,628,064,81
6,402,0832,5 %4,326,694,27
4,040,4611,39 %3,584,683,57
3,410,247,04 %3,173,703,06
3,320,175,12 %3,153,742,98
2,970,6521,89 %2,323,482,26
2,540,8332,68 %1,712,751,57
1,37−0,28−20,44 %1,652,061,33
1,31−0,17−12,98 %1,481,501,30
1,43−0,14−9,79 %1,571,581,39
1,59−0,14−8,81 %1,731,751,57
1,70−0,09−5,29 %1,791,811,65
1,810,031,66 %1,781,831,75
1,73−0,04−2,31 %1,771,801,69
1,810,000 %1,811,871,75
1,80−0,12−6,67 %1,921,921,74
1,89−0,05−2,65 %1,941,951,88
1,91−0,03−1,57 %1,942,001,88
1,940,000 %1,941,981,88
1,950,042,05 %1,912,001,86
1,90−0,30−15,79 %2,202,271,88
2,020,041,98 %1,982,071,90
1,97−0,03−1,52 %2,002,051,91
2,000,000 %2,002,141,99
1,99−0,01−0,5 %2,002,101,96
2,010,136,47 %1,882,031,81
1,90−0,07−3,68 %1,972,001,83
1,93−0,05−2,59 %1,981,981,92
1,93−0,06−3,11 %1,992,001,88
1,970,063,05 %1,912,001,86
1,810,021,1 %1,791,851,69
1,77−0,31−17,51 %2,082,081,75
2,030,031,48 %2,002,031,83
2,050,125,85 %1,932,221,81
1,73−0,05−2,89 %1,781,831,63
1,650,042,42 %1,611,721,58
1,60−0,18−11,25 %1,781,871,60
1,730,095,2 %1,641,801,64
1,64−0,05−3,05 %1,691,731,61
1,690,1911,24 %1,501,721,50
1,56−0,14−8,97 %1,701,701,53
1,770,010,56 %1,761,801,71
1,79−0,24−13,41 %2,032,031,78
1,990,000 %1,992,111,97
1,960,115,61 %1,852,011,85
1,840,2815,22 %1,561,841,55
1,53−0,01−0,65 %1,541,581,44
1,530,159,8 %1,381,531,36
1,370,042,92 %1,331,441,31
1,320,139,85 %1,191,371,18
1,18−0,02−1,69 %1,201,211,17
1,23−0,03−2,44 %1,261,311,21
1,26−0,11−8,73 %1,371,371,25
1,390,000 %1,391,411,30
1,390,032,16 %1,361,421,30
1,37−0,04−2,92 %1,411,431,34
1,39−0,01−0,72 %1,401,481,36
1,42−0,03−2,11 %1,451,451,40
1,440,010,69 %1,431,461,39
1,450,000 %1,451,511,42
1,460,074,79 %1,391,501,35
1,37−0,06−4,38 %1,431,471,33
1,43−0,05−3,5 %1,481,501,35
1,48−0,10−6,76 %1,581,581,43
1,53−0,07−4,58 %1,601,641,50
1,580,063,8 %1,521,591,50
1,53−0,04−2,61 %1,571,601,50
1,58−0,13−8,23 %1,711,741,56
1,71−0,08−4,68 %1,791,821,67
1,78−0,06−3,37 %1,841,881,74
1,77−0,13−7,34 %1,901,951,75
1,85−0,13−7,03 %1,981,981,78
1,990,084,02 %1,912,091,91
1,960,063,06 %1,901,981,87
1,87−0,02−1,07 %1,891,901,80
1,850,115,95 %1,741,871,73
1,69−0,03−1,78 %1,721,731,65
1,68−0,09−5,36 %1,771,771,60
1,710,000 %1,711,741,62
1,74−0,14−8,05 %1,881,911,69
1,820,021,1 %1,801,861,76
1,82−0,12−6,59 %1,942,001,82
1,920,105,21 %1,821,951,77
1,810,179,39 %1,641,831,64
1,64−0,16−9,76 %1,801,811,60
1,790,3217,88 %1,471,791,36
1,47−0,17−11,56 %1,641,671,44
1,560,2113,46 %1,351,591,29

Susijusios diskusijos

Radar19

prieš 3 savaites

Min +100%

Company by this prices valued 4 mln got almost 40 mln credits. Has idea's.. Who so full... Or so trust?

Sparcks

prieš 3 savaites

OTC

Nasdaq will suspend trading of BTAI on September 8, 2026, and the company says it doesn't plan to contest the delisting. After that, the shares are expected to move to OTC Pink Limited Thats why the price drop , i think we go down more

Sparcks

prieš 3 savaites

i dont understant anymore

who sell? why this price tank so mytch , we going to zero ?

Sparcks

prieš 3 savaites

9 oct is the date

October 9, 2026 → the deadline for submitting bids ("Qualified Bids") that can compete with Teva's offer. October 14, 2026 → is the scheduled date for the auction, if needed. If a better offer comes in by October 9, Teva can overbid, and the other bidders can keep competing in the auction. After the auction, the result still has to be approved by the bankruptcy court, so October 14 doesn’t necessarily mean the deal will be finally closed that day. So during this time the stock price might fluctuate , good luck all

Radar19

prieš 3 savaites

Short comment

Now company is on better situation than before Chapter 11. But price is 4 times lower. Question... How long it will be on this low level?

Radar19

prieš 3 savaites

1st target 0.24

Check last 24h.. News.. Selling assets min 57 mln

StockyMan

prieš 3 savaites

Watch this

With a predicted analyst price of 18$ someone is gonna buy this at the last minute so holding on because the drug is too good to lose so soon before approval watch this space DYOR!

pedrothecat

prieš 3 savaites

🤑

I bought 100 quid worth of shares at these levels Give a mad man money don’t be surprised when he does some mad SH-T

Sparcks

prieš 3 savaites

ITS DONE

it's over, the bullies will sell iglamy and we will lose all our money, only a miracle will come for another buyer to offer more, a few days ago a member of the management left for another company, I think he knew what was coming, so only a miracle can save us, another buyer has to come and offer over 100 million for us to receive something, the management will receive their salaries and bonuses so for them I don't think it's too big a loss!!

Sparcks

prieš 3 savaites

Game over

Guest thats it, shorters won , i think btai cant pay and ppl start to sell

Sparcks

praėjusį mėnesį

55% Off Premium BioXcel’s BXCL501 Agitation Study Completion: What Investors Should Watch Next

https://www.tipranks.com/news/company-announcements/bioxcels-bxcl501-agitation-study-completion-what-investors-should-watch-next

Oliver11

prieš 2 mėnesius

Moon 🌕

News inc. I hope, huge potential

Nitrocooler

prieš 2 mėnesius

Snapshot

Snapshot

Oliver11

prieš 2 mėnesius

Movement

Any idea where we could go tdy?

Kennyup

prieš 3 mėnesius

One to watch

$BTAI has had great success in phase 1, 2 and 3 trails. The PDUFA decision has a target date of novemeber the 14th 2026 I expect speculative volume getting closer to the decision date. Be aware if approved the stock could lock in some highly significant gains. There is always risk involved if denied it could experience a heavy drop. Good luck and safe trading👍 NFA

Sparcks

prieš 3 mėnesius

BioXcel Therapeutics, Inc.(NasdaqCM:BTAI) added to Russell 3000E Growth Benchmark

Good news

Šiame puslapyje gali būti bendruomenės sukurto turinio, už kurį „Trading 212“ neatsako. Visada atlik savo tyrimą. „Trading 212“ teikia tik vykdymo paslaugą, bet neteikia investavimo konsultacijų ar portfelio valdymo paslaugų.

Investavimas be komisinių visiems

Pirk ir parduok Bioxcel Therapeutics Inc −0,0096 $ (14,2 %) ir daugiau nei 13 000 pasaulinių vertybinių popierių ir ETF

Gali būti taikomi kiti mokesčiai. Žr. mūsų sąlygas ir mokesčius.

Peržiūrėk mūsų sąlygas ir mokesčius čia

phone

Įsigyk vertybinių popierių iškart

Pasirink mėgstamiausią įmonę

Pasirink, kiek investuoti

Gauk akcijų per kelias sekundes

Turto kaupimas – įprotis.
Automatizuokite jį naudodami Pies.

Investuok į paruoštus arba susikurk savo investicijų rinkinius, pasirinkdamas iš daugybės vertybinių popierių ir ETF

Sužinok daugiau

Sužinok daugiau

Žiūrėti vaizdo įrašą

Turėk net brangiausių akcijų, tokių kaip „Google“, „Amazon“ ir „Apple“

Žiūrėti vaizdo įrašą

Peržiūrėk visas prekybos priemones

Pagalba visą parą

29 sekundžių vidutinis atsako laikas

Pradėk kaupti turtą jau dabar

Prisijunk prie daugiau nei 5 mln. naudotojų

Atsisiųsti programėlę

Atidaryti sąskaitą

Atsisiųsk mobiliąją programėlę

qr-code

Visi pateikti statistiniai duomenys yra globalūs. Klientų skaičius atspindi finansuotas sąskaitas.

Puiku

Įvertinta 4,6/5, remiantis 103 187 atsiliepimais apie

Trustpilot

Įvertinta 4,6/5, remiantis 103 187 atsiliepimais apie

Trustpilot

Pakviestas

Easy to understand + use

Feel confident that my money is safe and invested carefully

Pakviestas

New Account

Easy to open an account and the app is straightforward and informative

Pakviestas

My money is growing so much quicker in…

My money is growing so much quicker in this account than any other. The app is so easy to use!

Pakviestas

Ease of use for beginners and minute by…

Ease of use for beginners and minute by minute updates. Also, news bulletins are great to follow.

Pakviestas

Easy to use

Easy to use. Lots of info on stocks. I’m a beginner only trading from August 2025. And making some profits through the year.

Pakviestas

Great app!

Great app!! Simple & intuitive!!

Pakviestas

Cash ISA investment

It has been very easy to make the investment in a cash ISA and track it on the app.

Pakviestas

Really easy to use, great app

Really easy to use, transfers are super quick and the interest rate is phenomenal. Great app.

Pakviestas

The App is excellent.

The App is excellent and very secure.

Pakviestas

I like the way they keep you informed.

I like the way they keep you informed.

Pakviestas

Excellent ISA Experience

ISA Fractional shares at low cost and great app with lots of markets. My held cash gets excellent interest rate. This helps me to wait for the right moment before investing.

Best broker app by far

I’ve had an excellent experience with Trading 212. The app is exceptionally well designed, with a clean, intuitive UI that makes investing feel simple without compromising on functionality. I particularly love features like Pies, which make it incredibly easy to build and manage a diversified portfolio, as well as the clear and well-presented performance metrics. It’s easy to understand how your investments are performing at a glance, which is something many other platforms struggle to get right. The fees are also very competitive, making Trading 212 particularly attractive for long-term investors. The combination of low costs, excellent functionality, interests paid daily on uninvested cash and a genuinely user-friendly experience makes it the best investing platforms I’ve used. Overall, a fantastic app that keeps adding useful features while remaining incredibly easy to use. Highly recommended for both beginners and more experienced investors.

Pakviestas

Keeping it low cost and simple

Great for both cash and stocks & shares ISA's as well as SIPP's

Pakviestas

Kept well informed on how my investment…

Kept well informed on how my investment is progressing

Pakviestas

Simple to use for someone like me

Simple to use for someone like me . Easy to add or withdraw

Pakviestas

I love it

I love it, watching the interest being added every day, being able to take money out when short abd putting as much as you can in when ever you want. I find it good to help my self be careful with money. I tell everybody how good it is.

Pakviestas

Easy to use

Easy to use, love seeing the interest increasing each day. Simple to install on iPhone, although tricky on android

Pakviestas

Good Shares ISA

Have used a zero fee competitor. Trading 212 beats them for speed of deposits and withdrawals. They also charge a lower fee for currency conversions. Transfer in of a cash ISA was efficiently handled. Make sure you use instant bank transfers, rather than cards or ApplePay for deposits. Cards work fine until you exceed a lifetime total deposit of £2000 (after which they have a 0.7% fee).

Pakviestas

Great for nervous newbie investors

I have been very pleasantly surprised at the good selection of ETF’s and company shares available on this platform. Armed with a little information gleaned from you tube videos I found the site simple to navigate and the purchasing tools very easy and intuitive. I can place an instruction to sell or purchase at a particular price point which I really like. I can track prices on my own investments and also monitor other potential investments. My only regret is that I didn’t sign up sooner.

Pakviestas

Great service with best initial interezt rate

Good interest rate, clear display of account status, easy to explore website, timely execution of withdrawal requests

Pateikiami keli teigiami mūsų klientų atsiliepimai

Mūsų apdovanojimai

Dažniausiai užduodami klausimai

Kokia yra Bioxcel Therapeutics akcijos kaina?

Dabartinė Bioxcel Therapeutics kaina yra 0,06 $.

Koks yra Bioxcel Therapeutics52 savaičių maksimumas?

52 savaičių maksimumas Bioxcel Therapeutics yra 2,96 $.

Koks yra Bioxcel Therapeutics 52 savaičių žemiausias lygis?

52 savaičių žemiausias Bioxcel Therapeutics kursas yra 0,02 $.

Koks yra Bioxcel Therapeutics savaitės rezultatas?

Per pastarąją savaitę Bioxcel Therapeutics kaina pasikeitė 28,32 %.

Koks yra Bioxcel Therapeutics mėnesio našumas?

Per pastarąjį mėnesį Bioxcel Therapeutics kaina pasikeitė −93,48 %.

Koks yra Bioxcel Therapeutics 3 mėnesių rezultatas?

Per pastaruosius tris mėnesius Bioxcel Therapeutics kaina pasikeitė −95,13 %.

Koks yra Bioxcel Therapeutics 6 mėnesių rezultatas?

Per pastaruosius šešis mėnesius Bioxcel Therapeutics kaina pasikeitė −96,65 %.

Koks yra Bioxcel Therapeuticsmetinis našumas?

Per pastaruosius metus Bioxcel Therapeutics kaina pasikeitė −98 %.